BioNTech Results Presentation Deck

BNT311 & BNT312: Phase 1/2 Expansion Cohorts Ongoing Next Generation Immunomodulators designed to prime & activate anti-tumor T-cell and NK cell function Part 1: Dose Escalation Part 2: Expansion Cohorts 21 GEN 1046/ BNT311 Anti- PD-L1 GEN1042/ BNT312 Anti- CD40 Anti- 4-1BB v Anti- 4-1BB Phase 1/2 Phase 1/2 Expansion dose: 100 mg Expansion dose: 100 mg TNBC 10 expansion cohorts are ongoing NSCLC Urothelial cancer Endometrial cancer HNSCC Cervical cancer n = up to 40 per cohort ● Monotherapy Expansion cohorts. Post-CPI melanoma (MOA) n = up to 22 per cohort • NSCLC • Combination expansion cohorts are currently recruiting Melanoma n = up to 40 per cohort ● BNT311 and BNT312: Programs partnered with Genmab; 50:50 profit/loss collaboration NK cell, natural killer cell; NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer; HNSCC, head and neck squamous cell carcinoma; MoA; mode of action; PDAC pancreatic ductile adenocarcinoma ● PDAC HNSCC BIONTECH Y

View entire presentation